Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
78 hedge funds and large institutions have $113M invested in Viracta Therapeutics, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 44 closing their positions.
100% more call options, than puts
Call options by funds: $1.81M | Put options by funds: $903K
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
25% less funds holding
Funds holding: 104 → 78 (-26)
52% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 44
70% less capital invested
Capital invested by funds: $380M → $113M (-$268M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$6.87M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$6.73M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.76M |
| 4 |
First Eagle Investment Management
New York
|
+$3.03M |
| 5 |
Morgan Stanley
New York
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$34.8M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$16.7M |
| 3 |
LCP
Lamond Capital Partners
San Francisco,
California
|
-$9.43M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$9.38M |
| 5 |
O
OrbiMed
New York
|
-$8.57M |
VIRX Hedge Fund Activity: Q4 2014 in Review
78 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2014, worth a combined $113M — down 70% from $380M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of VIRX and 21 opened new positions — a net loss of 23 holders — while 25 trimmed existing stakes and 21 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $6.87M. The largest seller was RA Capital Management, exiting entirely with an estimated $34.8M sold.
- 78 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2014, down from 104 in Q3 2014.
- Funds reported $113M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2014, down 70% quarter-over-quarter.
- 21 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2014 and 44 closed out, a net change of -23 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2014 was Baker Bros. Advisors, an estimated $6.87M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2014 was RA Capital Management, an estimated $34.8M sold.
Based on aggregated 13F filings for Q4 2014.